BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Papamichael K, Vermeire S. Withdrawal of anti-tumour necrosis factor α therapy in inflammatory bowel disease. World J Gastroenterol 2015; 21(16): 4773-4778 [PMID: 25944990 DOI: 10.3748/wjg.v21.i16.4773]
URL: https://www.wjgnet.com/1007-9327/full/v21/i16/4773.htm
Number Citing Articles
1
JG Sanchez-Hernandez, N Rebollo, F Munoz, A Martin-Suarez, MV Calvo. Therapeutic drug monitoring of tumour necrosis factor inhibitors in the management of chronic inflammatory diseasesAnnals of Clinical Biochemistry: International Journal of Laboratory Medicine 2019; 56(1): 28 doi: 10.1177/0004563218782286
2
Thomas P Chapman, Catarina Frias Gomes, Edouard Louis, Jean-Frédéric Colombel, Jack Satsangi. De-escalation of immunomodulator and biological therapy in inflammatory bowel diseaseThe Lancet Gastroenterology & Hepatology 2020; 5(1): 63 doi: 10.1016/S2468-1253(19)30186-4
3
N. Mitrev, N. Vande Casteele, C. H. Seow, J. M. Andrews, S. J. Connor, G. T. Moore, M. Barclay, J. Begun, R. Bryant, W. Chan, C. Corte, S. Ghaly, D. A. Lemberg, V. Kariyawasam, P. Lewindon, J. Martin, R. Mountifield, G. Radford-Smith, P. Slobodian, M. Sparrow, C. Toong, D. van Langenberg, M. G. Ward, R. W. Leong. Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseasesAlimentary Pharmacology & Therapeutics 2017; 46(11-12): 1037 doi: 10.1111/apt.14368
4
Hang Hock Shim, Cynthia H. Seow. Treatment of Inflammatory Bowel Disease with Biologics2018; : 141 doi: 10.1007/978-3-319-60276-9_10
5
Steven J. Bots, Sabine Kuin, Cyriel Y. Ponsioen, Krisztina B. Gecse, Marjolijn Duijvestein, Geert R. D’Haens, Mark Löwenberg. Relapse rates and predictors for relapse in a real-life cohort of IBD patients after discontinuation of anti-TNF therapyScandinavian Journal of Gastroenterology 2019; 54(3): 281 doi: 10.1080/00365521.2019.1582693
6
Leilei Zhu, Gil Y. Melmed. Treatment of Inflammatory Bowel Disease with Biologics2018; : 315 doi: 10.1007/978-3-319-60276-9_18
7
Samuel O Adegbola, Kapil Sahnan, Charlene Twum-Barima, Nusrat Iqbal, Lillian Reza, Phillip Lung, Janindra Warusavitarne, Phil Tozer, Ailsa Hart. Current review of the management of fistulising perianal Crohn’s diseaseFrontline Gastroenterology 2020; : flgastro-2020-101489 doi: 10.1136/flgastro-2020-101489
8
Joana Torres, Ray K. Boyapati, Nicholas A. Kennedy, Edouard Louis, Jean-Frédéric Colombel, Jack Satsangi. Systematic Review of Effects of Withdrawal of Immunomodulators or Biologic Agents From Patients With Inflammatory Bowel DiseaseGastroenterology 2015; 149(7): 1716 doi: 10.1053/j.gastro.2015.08.055
9
Catarina Frias Gomes, Thomas P Chapman, Jack Satsangi. De-escalation of medical therapy in inflammatory bowel diseaseCurrent Opinion in Pharmacology 2020; 55: 73 doi: 10.1016/j.coph.2020.09.014
10
Hiroshi Nakase, Motoi Uchino, Shinichiro Shinzaki, Minoru Matsuura, Katsuyoshi Matsuoka, Taku Kobayashi, Masayuki Saruta, Fumihito Hirai, Keisuke Hata, Sakiko Hiraoka, Motohiro Esaki, Ken Sugimoto, Toshimitsu Fuji, Kenji Watanabe, Shiro Nakamura, Nagamu Inoue, Toshiyuki Itoh, Makoto Naganuma, Tadakazu Hisamatsu, Mamoru Watanabe, Hiroto Miwa, Nobuyuki Enomoto, Tooru Shimosegawa, Kazuhiko Koike. Evidence-based clinical practice guidelines for inflammatory bowel disease 2020Journal of Gastroenterology 2021; 56(6): 489 doi: 10.1007/s00535-021-01784-1
11
Daniel J Wong, Eve M Roth, Joseph D Feuerstein, Vitaliy Y Poylin. Surgery in the age of biologicsGastroenterology Report 2019; 7(2): 77 doi: 10.1093/gastro/goz004
12
Konstantinos Papamichael, Adam S Cheifetz. Use of anti-TNF drug levels to optimise patient managementFrontline Gastroenterology 2016; 7(4): 289 doi: 10.1136/flgastro-2016-100685
13
Laura E. Targownik, Aruni Tennakoon, Stella Leung, Lisa M. Lix, Zoann Nugent, Harminder Singh, Charles N. Bernstein. Factors Associated with Discontinuation of Anti-TNF Inhibitors Among Persons with IBDInflammatory Bowel Diseases 2017; 23(3): 409 doi: 10.1097/MIB.0000000000001025
14
Rocío Sedano Muñoz, Rodrigo Quera Pino, Jaime Lubascher Correa, Gonzalo Pizarro Jofré, Daniela Simian Marín. Evaluation of de-escalation of anti-TNF-α therapy in inflammatory bowel diseaseGastroenterología y Hepatología (English Edition) 2019; 42(2): 133 doi: 10.1016/j.gastre.2019.02.013
15
Casper Steenholdt, Klaus Bendtzen, Jørn Brynskov, Mark A. Ainsworth. Optimizing Treatment with TNF Inhibitors in Inflammatory Bowel Disease by Monitoring Drug Levels and Antidrug AntibodiesInflammatory Bowel Diseases 2016; 22(8): 1999 doi: 10.1097/MIB.0000000000000772
16
Catarina Frias Gomes, Jean-Frédéric Colombel, Joana Torres. De-escalation of Therapy in Inflammatory Bowel DiseaseCurrent Gastroenterology Reports 2018; 20(8) doi: 10.1007/s11894-018-0643-8
17
J. Llaó, J.E. Naves, A. Ruiz-Cerulla, C. Romero, M. Mañosa, T. Lobatón, E. Cabré, J. Guardiola, E. Garcia-Planella, E. Domènech. Tratamiento de mantenimiento con azatioprina o infliximab en pacientes con colitis ulcerosa corticorrefractarios respondedores a las 3 dosis de inducción de infliximabEnfermedad Inflamatoria Intestinal al Día 2017; 16(1): 15 doi: 10.1016/j.eii.2016.06.001
18
Marcello Cintolo, Giuseppe Costantino, Socrate Pallio, Walter Fries. Mucosal healing in inflammatory bowel disease: Maintain or de-escalate therapyWorld Journal of Gastrointestinal Pathophysiology 2016; 7(1): 1-16 doi: 10.4291/wjgp.v7.i1.1
19
Samuel O. Adegbola, Kapil Sahnan, Janindra Warusavitarne, Ailsa Hart, Philip Tozer. Anti-TNF Therapy in Crohn’s DiseaseInternational Journal of Molecular Sciences 2018; 19(8): 2244 doi: 10.3390/ijms19082244
20
Feng Lv, Longbiao Yang, Jianxiu Wang, Zhixiang Chen, Qizhao Sun, Peiguo Zhang, Chentong Guan, Yanbin Liu. Inhibition of TNFR1 Attenuates LPS Induced Apoptosis and Inflammation in Human Nucleus Pulposus Cells by Regulating the NF-KB and MAPK Signalling PathwayNeurochemical Research 2021; 46(6): 1390 doi: 10.1007/s11064-021-03278-1
21
Ben Kang, So Yoon Choi, Young Ok Choi, Min-ji Kim, Kyunga Kim, Ji-Hyuk Lee, Yon Ho Choe. Subtherapeutic Infliximab Trough Levels and Complete Mucosal Healing Are Associated With Sustained Clinical Remission After Infliximab Cessation in Paediatric-onset Crohn’s Disease Patients Treated With Combined Immunosuppressive TherapyJournal of Crohn's and Colitis 2018; 12(6): 644 doi: 10.1093/ecco-jcc/jjy021
22
Rocío Sedano Muñoz, Rodrigo Quera Pino, Jaime Lubascher Correa, Gonzalo Pizarro Jofré, Daniela Simian Marín. Evaluación del retiro progresivo y/o la suspensión de la terapia anti-TNF-α en la enfermedad inflamatoria intestinalGastroenterología y Hepatología 2019; 42(2): 133 doi: 10.1016/j.gastrohep.2018.10.010
23
Taku Kobayashi, Satoshi Motoya, Shiro Nakamura, Takayuki Yamamoto, Masakazu Nagahori, Shinji Tanaka, Tadakazu Hisamatsu, Fumihito Hirai, Hiroshi Nakase, Kenji Watanabe, Takayuki Matsumoto, Masanori Tanaka, Takayuki Abe, Yasuo Suzuki, Mamoru Watanabe, Toshifumi Hibi, Shingo Kato, Atsushi Maemoto, Minoru Matsuura, Ryosuke Sakemi, Makoto Sasaki, Tomoyuki Tsujikawa, Motohiro Esaki, Norimasa Fukata, Kazuya Kitamura, Sakiko Hiraoka, Ryota Hokari, Shunji Ishihara, Tsutomu Mizoshita, Yuji Naito, Fumio Omata, Masayuki Saruta, Takuya Yoshino. Discontinuation of infliximab in patients with ulcerative colitis in remission (HAYABUSA): a multicentre, open-label, randomised controlled trialThe Lancet Gastroenterology & Hepatology 2021; 6(6): 429 doi: 10.1016/S2468-1253(21)00062-5